Cargando…

Development of a fingerprinting panel using medically relevant polymorphisms

BACKGROUND: For population based biorepositories to be of use, rigorous quality control and assurance must be maintained. We have designed and validated a panel of polymorphisms for individual sample identification consisting of 36 common polymorphisms that have been implicated in a wide range of di...

Descripción completa

Detalles Bibliográficos
Autores principales: Cross, Deanna S, Ivacic, Lynn C, McCarty, Catherine A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684120/
https://www.ncbi.nlm.nih.gov/pubmed/19379518
http://dx.doi.org/10.1186/1755-8794-2-17
_version_ 1782167170575237120
author Cross, Deanna S
Ivacic, Lynn C
McCarty, Catherine A
author_facet Cross, Deanna S
Ivacic, Lynn C
McCarty, Catherine A
author_sort Cross, Deanna S
collection PubMed
description BACKGROUND: For population based biorepositories to be of use, rigorous quality control and assurance must be maintained. We have designed and validated a panel of polymorphisms for individual sample identification consisting of 36 common polymorphisms that have been implicated in a wide range of diseases and an additional sex marker. This panel uniquely identifies our biorepository of approximately 20,000 samples and would continue to uniquely identify samples in biorepositories of over 100 million samples. METHODS: A panel of polymorphisms associated with at least one disease state in multiple populations was constructed using a cut-off of 0.20 or greater confirmed minor allele frequency in a European Caucasian population. The fingerprinting assay was tested using the MALDI-TOF mass spectrometry method of allele determination on a Sequenom platform with a panel of 28 Caucasian HapMap samples; the results were compared with known genotypes to ensure accuracy. The frequencies of the alleles were compared to the expected frequencies from dbSNP and any genotype that did not achieve Hardy Weinberg equilibrium was excluded from the final assay. RESULTS: The final assay consisted of the AMG sex marker and 36 medically relevant polymorphisms with representation on each chromosome, encompassing polymorphisms on both the Illumina 550K bead array and the Affymetrix 6.0 chip (with over a million polymorphisms) platform. The validated assay has a P(ID) of 6.132 × 10(-15 )and a P(sib)(ID) of 3.077 × 10(-8). This assay allows unique identification of our biorepository of 20,000 individuals as well and ensures that as we continue to recruit individuals they can be uniquely fingerprinted. In addition, diseases such as cancer, heart disease diabetes, obesity, and respiratory disease are well represented in the fingerprinting assay. CONCLUSION: The polymorphisms in this panel are currently represented on a number of common genotyping platforms making QA/QC flexible enough to accommodate a large number of studies. In addition, this panel can serve as a resource for investigators who are interested in the effects of disease in a population, particularly for common diseases.
format Text
id pubmed-2684120
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26841202009-05-20 Development of a fingerprinting panel using medically relevant polymorphisms Cross, Deanna S Ivacic, Lynn C McCarty, Catherine A BMC Med Genomics Research Article BACKGROUND: For population based biorepositories to be of use, rigorous quality control and assurance must be maintained. We have designed and validated a panel of polymorphisms for individual sample identification consisting of 36 common polymorphisms that have been implicated in a wide range of diseases and an additional sex marker. This panel uniquely identifies our biorepository of approximately 20,000 samples and would continue to uniquely identify samples in biorepositories of over 100 million samples. METHODS: A panel of polymorphisms associated with at least one disease state in multiple populations was constructed using a cut-off of 0.20 or greater confirmed minor allele frequency in a European Caucasian population. The fingerprinting assay was tested using the MALDI-TOF mass spectrometry method of allele determination on a Sequenom platform with a panel of 28 Caucasian HapMap samples; the results were compared with known genotypes to ensure accuracy. The frequencies of the alleles were compared to the expected frequencies from dbSNP and any genotype that did not achieve Hardy Weinberg equilibrium was excluded from the final assay. RESULTS: The final assay consisted of the AMG sex marker and 36 medically relevant polymorphisms with representation on each chromosome, encompassing polymorphisms on both the Illumina 550K bead array and the Affymetrix 6.0 chip (with over a million polymorphisms) platform. The validated assay has a P(ID) of 6.132 × 10(-15 )and a P(sib)(ID) of 3.077 × 10(-8). This assay allows unique identification of our biorepository of 20,000 individuals as well and ensures that as we continue to recruit individuals they can be uniquely fingerprinted. In addition, diseases such as cancer, heart disease diabetes, obesity, and respiratory disease are well represented in the fingerprinting assay. CONCLUSION: The polymorphisms in this panel are currently represented on a number of common genotyping platforms making QA/QC flexible enough to accommodate a large number of studies. In addition, this panel can serve as a resource for investigators who are interested in the effects of disease in a population, particularly for common diseases. BioMed Central 2009-04-20 /pmc/articles/PMC2684120/ /pubmed/19379518 http://dx.doi.org/10.1186/1755-8794-2-17 Text en Copyright © 2009 Cross et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Cross, Deanna S
Ivacic, Lynn C
McCarty, Catherine A
Development of a fingerprinting panel using medically relevant polymorphisms
title Development of a fingerprinting panel using medically relevant polymorphisms
title_full Development of a fingerprinting panel using medically relevant polymorphisms
title_fullStr Development of a fingerprinting panel using medically relevant polymorphisms
title_full_unstemmed Development of a fingerprinting panel using medically relevant polymorphisms
title_short Development of a fingerprinting panel using medically relevant polymorphisms
title_sort development of a fingerprinting panel using medically relevant polymorphisms
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684120/
https://www.ncbi.nlm.nih.gov/pubmed/19379518
http://dx.doi.org/10.1186/1755-8794-2-17
work_keys_str_mv AT crossdeannas developmentofafingerprintingpanelusingmedicallyrelevantpolymorphisms
AT ivaciclynnc developmentofafingerprintingpanelusingmedicallyrelevantpolymorphisms
AT mccartycatherinea developmentofafingerprintingpanelusingmedicallyrelevantpolymorphisms